PRLD: Psyros POC system development accelerates, with new funding and strong market growth outlook

About this update from Prolight Diagnostics Ab

Prolight Diagnostics advanced its Psyros POC system, secured SEK 12.6 million via warrant exercise, and maintained a strong cash position despite ongoing losses as it prepares for clinical validation in 2025. POC and cardiac biomarker markets show robust growth potential.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Prolight Diagnostics Ab